A new study at a single center in Japan found no significant differences in the rate of BRCA mutations between ovarian cancer patients with or without family histories of the mutations and recommends that BRCA1/2 testing be required for all ovarian cancer patients
A recent study that gave hormone therapy to ovarian cancer patients with severe menopausal symptoms revealed that the treatment had a beneficial survival effect.
Here we discuss the advantages and pitfalls of HIPEC in advanced ovarian cancer, as well as current data and ongoing prospective trials.
Clinical Trials of Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Unanswered Questions
Based on the currently available scientific evidence, HIPEC should not be considered a standard therapeutic option after optimal cytoreduction in advanced ovarian cancer, nor should it be offered outside of a clinical trial.
The evidence suggests that few centers offer IP therapy routinely. Why? The answer may be that oncologists simply don’t know what to do. There have been three completely distinct regimens, none of which has been used in the outpatient setting.
A small study showed that treatment with the anti-PD-1 immunotherapy nivolumab was able to produce complete responses in patients with advanced platinum-resistant ovarian cancer.
Beta-blockers were associated with increased overall survival in women with epithelial ovarian cancer, according to a retrospective study.
Testing women for non-BRCA gene mutations that can confer breast or ovarian cancer risk has clinical management consequences for both the women and their family members.
Women younger than 35 with low-grade serous carcinoma of the ovary or peritoneum or those who still had persistent disease at the completion of primary therapy were found to have worse disease outcomes.
A study has found that mutations in the genes RAD51C and RAD51D confer risk for epithelial ovarian cancer, causing approximately one in every 90 high-grade and one in every 120 epithelial ovarian cancer occurrences.